Objective-Although stem cell factor (SCF) has been shown to play a critical role in hematopoiesis, gametogenesis, and melanogenesis, the function of SCF in the regulation of vascular integrity has not been studied. Approach and Results-We demonstrated that SCF binds to and activates the cKit receptor in endothelial cells, thereby increasing the internalization of vascular endothelial-cadherin and enhancing extravasation of dyes to a similar extent as vascular endothelial growth factor. SCF-mediated cKit activation in endothelial cells enhanced the phosphorylation of endothelial nitric oxide (NO) synthase via the phosphoinositide 3-kinase/Akt signaling pathway and subsequently increased the production of NO. Inhibition of endothelial NO synthase expression and NO synthesis using small interfering RNA knockdown and chemical inhibitors substantially diminished the ability of SCF to increase the internalization of vascular endothelial-cadherin and in vitro endothelial permeability. SCF-induced increase in extravasation of the dyes was abrogated in endothelial NO synthase knockout mice, which indicates that endothelial NO synthase-mediated NO production was responsible for the SCF-induced vascular leakage. Furthermore, we demonstrated that the expression of SCF and cKit was significantly higher in the retina of streptozotocin-injected diabetic mice than in the nondiabetic control animals. Depletion of SCF by intravitreous injection of anti-SCF-neutralizing immunoglobulin G significantly prevented vascular hyperpermeability in the retinas of streptozotocin-injected diabetic mice. Conclusions-Our data reveal that SCF disrupts the endothelial adherens junction and enhances vascular leakage, as well as suggest that anti-SCF/cKit therapy may hold promise as a potential therapy for the treatment of hyperpermeable vascular diseases. (Arterioscler Thromb Vasc
T he endothelium lining the blood vasculature forms an interface between the blood and tissues and plays a crucial role in controlling the blood-to-tissue movement of plasma proteins, solute, and water. Under normal physiological conditions, transvascular exchange is modulated by hydrostatic and oncotic forces, the concentration gradient of solutes acting across the vascular walls, and the surface areas. 1 All these factors are affected by changes in vascular hemodynamics such as blood flow, blood pressure, and the number of perfused blood vessels. For example, an increase in transvascular exchange is most probably the result of vasodilation that increases the number of perfused vessels and the hydrostatic pressure within these vessels. Alternatively, the blood-to-tissue movement also occurs through paracellular pathway. Paracellular passage is governed by the opening and closing of endothelial cell-cell junctions where adherens junction proteins are critically involved in intercellular junction assembly. 2 The integrity of the endothelial barrier can be disrupted by a variety of permeability factors such as vascular endothelial growth factor (VEGF), platelet-activating factor, and tumor necrosis factor. These factors promote endothelial barrier breakdown by inducing the phosphorylation and disassembly of adherens junction proteins such as vascular endothelial (VE)-cadherin, β-catenin, and p120-catenin. [3] [4] [5] In addition, these factors have been reported to increase endothelial permeability via activation of the endothelial nitric oxide synthase (eNOS) pathway. For example, VEGF-or platelet activating factor-induced vascular permeability was markedly reduced in eNOS-deficient mice or ECs, suggesting that eNOS-derived NO is another key signaling element in the regulation of endothelial permeability. 6, 7 Furthermore, these permeability factors have been shown to elicit vascular hyperpermeability in several pathological conditions including diabetes mellitus (DM), ischemia, and sepsis. Thus, it is important to understand how these permeability factors disrupt endothelial barrier integrity and also to identify novel molecules that regulate endothelial permeability.
Stem cell factor (SCF), which is also known as Steel factor, is the ligand of the cKit proto-oncogene. 8, 9 SCF has been July 2014 previously described as a multifunctional cytokine involved in hematopoiesis, gametogenesis, and melanogenesis. [10] [11] [12] In divergent cell types, SCF has been demonstrated to play an essential role in the regulation of cell survival, proliferation, differentiation, and migration. However, the role of SCF in ECs has not yet been fully determined, although the results of several studies have shown that the SCF/cKit pathway contributes to angiogenesis and vascular regeneration. [13] [14] [15] Interestingly, the result of our previous studies revealed that SCF-mediated cKit activation in ECs and endothelial progenitor cells induced a phosphorylation of multiple downstream signaling molecules including eNOS. 14 Given that eNOS activation and subsequent NO synthesis are key signaling events in eliciting endothelial hyperpermeability, we proposed that SCF might regulate endothelial permeability. In the present study, we aimed to investigate the novel role of SCF in the regulation of endothelial permeability, as well as to determine its contribution to retinal vascular leakage in streptozotocin (STZ)-injected diabetic mice.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

SCF Enhances Endothelial Permeability
First, we determined the endothelial paracellular permeability in response to SCF. SCF significantly increased the passage of fluorescein isothiocyanate (FITC)-labeled dextran across human umbilical vein endothelial cell (HUVEC) monolayer ( Figure 1A ). In transmission electron microscopy analysis, we found that SCF induced the disruption of endothelial cell-cell interaction ( Figure 1B ). Becaue the disassembly of adherens junction proteins such as VE-cadherin has been known to increase endothelial paracellular permeability, we then investigated whether SCF might alter the localization of VE-cadherin at the cell-cell border using a protocol adopted from Gavard and Gutkind. 16 In nonstimulated HUVECs, VE-cadherin was coaligned with tight junction molecules such as zonula occludens (ZO)-1 at endothelial cell-cell junctions ( Figure 1C ; Figure I in the online-only Data Supplement). In contrast, SCF stimulation resulted in the accumulation of acid washresistant intracellular VE-cadherin, where most of the intracellular VE-cadherin was colocalized with the early endosome antigen-1. Furthermore, in retinal vascular permeability assay, intravitreous injection of SCF induced ≈2-fold extravasation of FITC-dextran compared with that induced by PBS injection ( Figure 1D ). The diffuse hyperfluorescent background and perivascular hyperfluorescence in SCF-or VEGF-treated retina indicated vascular leakage of fluorescent dextrans. The Miles assay also revealed that intradermal injection of SCF significantly enhanced the deposition of Evans blue dye ( Figure 1E ). Compared with VEGF, SCF exhibited similar potency in increasing vascular leakage in retinal and dermal vasculature. We then investigated whether VE-cadherin distribution might be altered in SCF-treated tissues. The immunofluorescence analysis of VE-cadherin expression in the retina of SCF-and PBS-treated mice revealed that VE-cadherin was found primarily on the endothelial cell surface in PBS-treated retina. In contrast, SCF stimulation induced focal loss in the staining of VE-cadherin in endothelial cells ( Figure IIA and IIB in the online-only Data Supplement). Scale bar, 20 μm. Quantification of the internalized VE-cadherin was performed as previously described (*P<0.05, #P>0.05 vs PBS; 3 independent experiments). F, Imatinib blocks the SCF-induced increase in dermal vascular leakage. PBS or imatinib (20 mg/kg) was intraperitoneally administered 30 min before SCF (50 ng) injection. The OD at 620 nm is expressed as a fold increase±SEM with respect to PBS control (*P<0.05, #P>0.05 vs PBS; n=3). July 2014
SCF-Induced Increases in Endothelial Permeability Are Mediated by the cKit Receptor
To investigate whether SCF-induced increases in endothelial permeability are mediated by cKit, we determined the endothelial paracellular permeability in HUVECs where cKit expression was suppressed by transfection with cKitspecific small interfering RNA. Reduced cKit mRNA levels in HUVECs were confirmed using reverse transcription polymerase chain reaction (Figure 2A ). Knockdown of cKit expression in HUVECs abrogated SCF-induced endothelial paracellular permeability to FITC-dextran ( Figures 2B) . These findings were also confirmed in studies using a pharmacological inhibitor of cKit, imatinib mesylate, which blocked SCF-induced phosphorylation of cKit in HUVECs ( Figure 2C ). Pretreatment with imatinib substantially diminished the SCF-induced endothelial permeability ( Figure 2D ). Moreover, imatinib also blocked the SCF-induced internalization of VE-cadherin ( Figure 2E ; Figure III in the online-only Data Supplement). In the Miles assay, intraperitoneal injection of imatinib substantially abrogated the SCF-induced increase in vascular leakage ( Figure 2F ). These data indicated that the expression and phosphorylation of cKit in ECs were required for SCF-induced endothelial hyperpermeability.
SCF-Induced Increase in Vascular Leakage Occurs Independently of VEGF Receptor 2 Activation
We next investigated whether SCF-induced increase in vascular leakage involved activation of VEGF receptor 2 (VEGFR2) pathway. Western blotting analysis revealed that SCF was not capable of phosphorylating VEGFR2 in HUVECs ( Figure 3A ). These results were further supported by the findings of in vitro and in vivo studies using the VEGFR2 inhibitor, SU1498. In addition, the results of endothelial paracellular permeability assays demonstrated that pretreatment with SU1498 did not alter the SCF-induced increase in endothelial permeability, although it completely blocked VEGF-induced hyperpermeability ( Figure 3B ). Furthermore, in a retinal permeability assay, SU1498 did not affect SCF-induced increase in vascular leakage ( Figure 3C ).
SCF Enhanced Endothelial Permeability by Promoting eNOS-Mediated NO Production
We have previously observed that binding of SCF to the cKit receptor in ECs resulted in the activation of multiple downstream signaling molecules including eNOS ( Figure 4A ). However, pretreatment with phosphoinositide 3-kinase or Akt inhibitors abrogated SCF-induced eNOS activation, which indicated that the interaction between SCF and cKit phosphorylated eNOS via the phosphoinositide 3-kinase/Akt pathway ( Figure 4B ). Because eNOS activation and subsequent NO generation play a predominant role in the regulation of vascular permeability, we examined whether eNOS-induced NO might participate in SCF-induced endothelial permeability. We found that SCF stimulation resulted in the enhanced production of nitrite in HUVECs to a similar extent as VEGF stimulation ( Figure 4C ). When the expression of cKit or eNOS was silenced using small interfering RNA-mediated knockdown (Figure 4D) , the SCF-induced increase in nitrite production was reduced to a similar level as that in untreated controls ( Figure 4E ), which indicated that SCF promoted NO production via activation of the cKit/eNOS pathway. Next, we assessed whether SCF might increase endothelial permeability by enhancing eNOS-mediated NO production. Knockdown of eNOS expression by using small interfering RNA transfection and blockade of eNOS-mediated NO production by using N w -nitro-l-arginine methyl ester substantially diminished the ability of SCF to promote endothelial paracellular permeability ( Figure 4F and 4G) . In a VE-cadherin internalization assay, pretreatment with N w -nitro-l-arginine methyl ester inhibited SCF-induced VE-cadherin endocytosis ( Figure 4H ; Figure IV in the online-only Data Supplement). Moreover, the addition of the NO donor, NONOate, significantly increased VE-cadherin endocytosis ( Figure 4I ; Figure V in the onlineonly Data Supplement). To determine whether eNOS was required in SCF-induced increase in vascular leakage, we performed retinal vascular permeability and Miles assays in agematched wild-type and eNOS −/− mice. An intravitreal injection of SCF into eNOS −/− mice did not increase extravasation of FITC-dextran in retinal vasculature ( Figure 4J) . Similarly, the results of the Miles assay revealed that intradermal injection of SCF did not enhance the deposition of Evans blue dye in eNOS −/− mice ( Figure 4K ). Taken together, these data indicated that SCF-induced vascular permeability predominantly occurred via eNOS-mediated NO production.
Intravitreal Injection of Anti-SCF Immunoglobulin G Inhibits Retinal Vascular Leakage in STZ-Injected Diabetic Mice
Because Figure 1D reveals that the intravitreal injection of SCF significantly increased retinal vascular leakage, we hypothesized that SCF might contribute to the early retinal vascular hyperpermeability in diabetic mice. We first examined whether the expression of SCF and cKit might be altered in the retina of STZ-injected diabetic mice. Two weeks after STZ injection, a time point when the retinal vascular leakage has been known to occur, quantitative reverse transcription polymerase chain reaction analysis was performed using retina tissue harvested from diabetic (DM) and nondiabetic (non-DM) mice. 17 The expression of both SCF and cKit was significantly higher in the retina of DM mice than in the retina of non-DM control mice ( Figure 5A ). Immunohistochemical analysis showed that the SCF signal was detected in the nuclear layer, which contained ganglion cells and astrocytes, in the retina of STZ-injected DM mice. In contrast, the SCF signal was not detected in the retina of non-DM mice ( Figure 5B ). In addition, cKit signal was highly increased in the retinal vascular endothelial cells of DM mice compared with non-DM controls ( Figure 5C ). The flow cytometry analysis also showed that cKit was mainly expressed in vascular endothelial cells in STZ-injected diabetic retinal tissues ( Figure VI in the online-only Data Supplement). We next determined whether depletion of SCF might prevent retinal vascular leakage in STZ-injected diabetic mice. Immediately after an intraperitoneal injection of STZ, the mice received an intravitreal administration of either anti-mouse SCF-neutralizing immunoglobulin G (IgG) or PBS. Two weeks after the initial STZ injection, the retina of the DM mice exhibited a focal perivascular leakage of FITCdextran and displayed diffuse hyperfluorescent background compared with non-DM controls ( Figure 6A ). However, the DM mice injected with anti-SCF-neutralizing IgGs did not demonstrate any clear evidence of retinal vascular leakage. Quantitative analysis of vascular leakage showed that retinal vascular leakage in DM mice treated with anti-SCF IgGs was low, similar to non-DM mice ( Figure 6B ). These data suggested that pretreatment with anti-SCF-neutralizing IgGs significantly blocked the development of vascular hyperpermeability in the retina of STZ-injected DM mice. In addition, we investigated whether SCF-induced increase in retinal vascular leakage in DM mice involved eNOS phosphorylation. Immunohistochemical analysis revealed that p-eNOS signal increased in the retinal vasculature of STZ-injected DM mice. The increase in p-eNOS labeling was abolished by the administration of anti-SCF-neutralizing IgGs ( Figure 6C ).
Discussion
SCF has been shown to play a key role in maintaining and reconstituting stem cell pools, particularly during the early stages of hematopoiesis and during the development of germ cells and melanocytes. However, the role of SCF in the regulation of vascular integrity remains largely unknown. In the present study, we demonstrated that SCF-mediated activation of its cognate receptor, cKit, increased endothelial permeability. The effect of SCF on vascular leakage was not mediated by VEGFR2 activation because the blockade of VEGFR2 activation with a chemical inhibitor did not inhibit SCF-induced extravasation. Moreover, SCF-induced vascular leakage contributed to the development of hyperpermeable vasculature in the retina of STZ-injected DM mice. Our data showed that SCF promoted endothelial permeability via eNOS-mediated NO production. SCF-induced cKit activation stimulated NO synthesis in ECs via phosphoinositide 3-kinase/Akt-dependent eNOS activation. Inhibition of eNOS expression and NO production using knockout mice, small interfering RNA knockdown, and chemical inhibitors completely abolished SCF-induced increase in endothelial permeability. The mechanism underlying eNOS-derived NO modulation of endothelial paracellular permeability has been recently studied. In ECs stimulated with VEGF or inflammatory cytokines, eNOS-derived NO induced S-nitrosylation of β-catenin and p120 catenin, which promoted their dissociation from VE-cadherin and contributed to the disassembly of adherens junctions and increased permeability. 18 It has also been reported that eNOS-derived NO nitrated tyrosine residues of p190 Rho GTPase-activating protein-A-induced RhoA activation and a concomitant increase in tensile strength, which resulted in the destabilization of endothelial adherens junctions consisting of VE-cadherins. 19, 20 These data may explain our findings that inhibition of NO synthesis by using an eNOS inhibitor substantially blocked the SCF-induced translocalization of VE-cadherin from the cell-cell border to the cytoplasm. However, NO is also an important endothelial-dependent vasodilator that increases vascular perfusion, thereby enhancing the blood-to-tissue exchange of water and solutes without a change in endothelial barrier integrity. In vivo assays used in this study do not separately measure the contribution of vasodilation-mediated hemodynamic change or increased permeability to the extravasation of macromolecular tracers. 21 Thus, the accumulation of macromolecular tracers in SCF-treated retinal and dermal tissues might partly be a result of NO-mediated vasodilation. Although the internalization and focal loss of VE-cadherin, which has been reported as a crucial step in the increase of vascular permeability, was observed in SCF-treated HUVECs and retinal tissues, more refined experiments should be performed to analyze the contribution of increased permeability to the accumulation of macromolecular tracers in vivo.
The results of this study also demonstrated that SCFinduced vascular hyperpermeability contributed to the development of retinal vascular leakage in STZ-injected diabetic mice. Our data showed that SCF was highly upregulated in the neural cell layers containing ganglion cells and astrocytes in the retina of DM mice compared with that in non-DM controls. Because the SCF promoter region contains putative κB sites and its transcription is increased on nuclear factor-κB binding, inflammation occurring in the early stages of STZinjected DM is likely to induce nuclear factor-κB and contribute to SCF upregulation. 22 SCF is expressed in 2 spliced variants, both of which initially exist as cell membranebound proteins, but are cleaved by proteases such as matrix metalloproteases for generating soluble proteins. 23, 24 Because the expression level of matrix metalloprotease-2 and matrix metalloprotease-9 has been reported to be increased in the retinas of diabetic animal models and in the vitreous fluid of patients with diabetic retinopathy, SCF expressed in the neural cells of STZ-injected DM mice is likely to be released as soluble forms that would subsequently bind to and activate cKit, which is also highly expressed in the retinal vasculature of DM mice. 25, 26 Moreover, depletion of upregulated SCF by intravitreal injection of anti-SCF-neutralizing IgGs significantly blocked the development of retinal vascular leakage in the retina of DM mice. These data suggest that SCF might play a crucial role in promoting retinal vascular permeability in the early stages of streptozotocin-injected murine DM.
Increased permeability of retinal vasculatures results in the accumulation of fluid and protein deposits in the macula (macular edema), which is the most common cause of vision loss in patients with DM. Currently, VEGF antagonists provide effective treatment for diseases with excessive vascular permeability. Indeed, several clinical studies have evaluated the efficacy of current VEGF antagonists for the treatment of diabetic macular edema (DME). 27 These studies demonstrated that anti-VEGF therapy was effective in reducing retinal/macular edema and improved the visual acuity outcomes in patients with DMEs >2 years. However, recent studies have revealed potential adverse effects of anti-VEGF therapy. For example, Kurihara et al 28 have reported that genetic deletion of VEGF-A in retinal pigment epithelial cells caused a dramatic loss of ECs lining choroidal vasculature and a severe vision loss in mice, raising issues about the long-term safety of VEGF antagonists. Moreover, the therapeutic response to anti-VEGF agents in DME seems to be variable and is much less robust compared with their effect in proliferative diabetic retinopathy. 29 Although VEGF has been shown to play a predominant role in inducing abnormal vessel growth and leakage in proliferative diabetic retinopathy, whether VEGF is also a major contributor to vascular permeability in DME is not evident. 29 These data indicate the need to identify additional molecular pathways that could be potential therapeutic targets in DME. Thus, our findings demonstrating VEGF-independent vasopermeable activity of SCF and its contribution in the development of hyperpermeable vasculature in STZ-injected DM mice have opened the possibility of using anti-SCF/cKit therapy for a therapeutic purpose to reduce vascular leakage in DME. Combinatorial therapy targeting both VEGF and SCF may maximize its therapeutic benefits in DME while minimizing the adverse effects of single VEGF suppression therapy.
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Figure 6.
Intravitreous injection of anti-stem cell factor (SCF)-neutralizing immunoglobulin G (IgG) inhibits the development of permeable vasculature in the retina of streptozotocin (STZ)-injected diabetic mice. A, Representative images of fluorescein isothiocyanate-dextran-perfused retina whole mounts after intravitreal injection of anti-mouse SCF-neutralizing IgGs or PBS in nondiabetic (non-DM) and diabetic (DM) mice. In the DM group, the mice received a single intravitreal injection of IgG (10 μg) or PBS on the same day as the initial STZ treatment. Two weeks later, vascular leakage was measured as previously described. Scale bar, 400 μm. B, The fluorescence intensity in the retina is expressed as the fold change±SEM with respect to PBS-injected non-DM control (*P<0.05; #P>0.05; n=4). C, Immunofluorescence staining was performed using anti-p-eNOS (green) and anti-CD31 IgGs (red) in retina sections. eNOS indicates endothelial nitric oxide synthase. The arrows indicate the double labeling of CD31 with p-eNOS. The nuclei are shown in blue (4′,6-diamidino-2-phenylindole). Scale bar, 50 μm.
